MNPR – monopar therapeutics inc. (US:NASDAQ)
Stock Stats
News
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "hold" rating re-affirmed by analysts at Jones Trading.
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments [Yahoo! Finance]
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $76.00 price target on the stock.
Form 4 Monopar Therapeutics For: Apr 02 Filed by: Tactic Pharma LLC
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Robinson Chandler
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Cittadine Andrew
Form 144 Monopar Therapeutics Filed by: Tactic Pharma LLC
Form 8-K Monopar Therapeutics For: Mar 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.